

KSE 100 Index statistics								
9-Dec-13								
24,998.89								
128.34								
151.46mn								

www.kse.com.pk

#### Alert on pharma sector:

## PPMA members to meet with authorities on 12th December 2013 on the issues

"As per the news reports a meeting is scheduled between Pakistan Pharmaceutical Manufacturers with relevant authorities on 12<sup>th</sup> December to discuss the issue of drug prices."

### Analyst:

Rajesh Kumar Maheshwari Tell: 111-111-721 Ext.116 www.scstrade.com

Valuation table is on next page...

Report could also be retrieved from Capital IQ – Blue Matrix

# Pharmaceutical industry - in search of amicable

### solution -

Pharmaceutical industry is one of the key industries in the country – we are laying focus on GLAXO, ABOT, SEARL, FEROZ & ICI.

The industry is trying to dictate terms wherein it is locked horns with the government to increase prices of medicines. The Prime Minister has asked the authorities to withdraw the notification of 10% - 12% price increase. We expect some amicable solution wherein MNCs dominated industry may play tactics of withdrawing key medicines from the market – thriving case for counterfeit or black market. We also expect government to present a long term solution which is also being presented in other sectors. (see our table of valuations on companies)

### Caveats:

Meeting between government and industry participants;

✓ MNCs to outwit government, since medicine quality is an important issue and price increase has already been done;

Product withdrawal threat;

 $\checkmark$  The MNCs are claiming that drug prices in Pakistan are lower than the other counties.

## Multinational companies withdrew key drugs:

We have come to know that local managements of MNCs have been asked by the parent companies to withdraw key products if required price increase is not allowed by the authorities and government. The companies are vying for pre-2001 formula where they are undertaking to expand.

### Vanishing key products in peak winter season

The demand of Anti- infectives , Anti-Viral and analgestic drugs usually increase in winter season, but our pharmaceutical market is facing acute shortage of these drugs like Panadol CF, Panadol Extra, Actifid P , Cofcol, Calpol , Panadol syrup, Xanax, Laxotanil, Sancos, Migril tablets, Ativan, Phenabarbiton, Arinac Forte, Decadron Inj., Marax Dihydan and Neuberol etc (as per our market survey. This situation creates a wide gap for the local unregistered products to fill this gap and making profit. Some of these brands belong to listed companies such as GLAXO, ABOT, SEARL etc.

## Pharmaceutical industry increases drugs' prices unilaterally:

Beside rejection of demand of price revision by federal government the pharmaceutical industry players have increased the drug prices by more than 20%.

Disclaimer: This report has been prepared by Standard Capital Securities (Pvt) Ltd and is provided for information purposes only. The information and data on which this report is based are obtained from sources which we believe to be reliable but we do not guarantee that it is accurate or complete. Standard Capital Securities (Pvt) Ltd accepts no responsibility whatsoever for any direct or indirect consequential loss arising from any use of this report or its contents. Investors are advised to take professional advice before making investments and Standard Capital Securities (Pvt) Ltd does not take any responsibility and shall not be held liable for undue reliance on this report. This report may not be reproduced, distributed or published by any recipient for any purpose.



The price of Panadol syrup is increased to Rs 51 which was previously selling at Rs 35. Likewise prices of Calpol syrup is expected to increase because supplier and wholesaler had vanished the product from market and expected to resume its supply with new price (Calpol & Pandol both are GLAXO products).

## Putting consumer's life on duplicate local drugs:

Our observation is that in order to put pressure on the government for increase in drugs prices, MNCs and national registered companies have stopped supplying key drugs to market. This created a gap for unregistered and duplicate drug manufacturer to enter in the market and supply their products. These duplicate products have many side effects which may lead to death of the patients.

We have already observed these type cases in Punjab due to use of these types of low quality drugs. The crisis could balloon and snowball to other province.

## Valuations deciphers that ABOT, SEARL and FEROZ still attractive — don't forget ICI

Table given below illustrates valuations of pharmaceutical industry;

- ✓ GLAXO yields highest PE of 27x with mere 3% dividend yield;
- ✓ SEARL & FEROZ yield lower PE of 8.6x and 8.3x (as per industry benchmarks; please also refer to our web portal <u>www.scstrade.com</u> pharma sector multiples in advance search).
- ✓ Wherein ABOT stands out as the strong company which is reporting highest cash per share of Rs 31.10 based on 9MCY13 results and yielding a PE of 16x which is attractive than GLAXO.
- ✓ ABOT is having a roaring success in nutritional segment which brackets it with companies such as NESTLE (PE 70x)
- ✓ Another company which comes to light is ICI for life sciences (report already released deciphering PE of 16x).

#### Pharmaceutical sector- snapshot Based on latest result

ialest result								
00400/42	Exp PE*	Dividend		EBIT	NPAT	Cash per		001
91010113		Yield	GP margin	margin	margin	share (Rs)	Book Value	PBV
2.95	26.7	3.0%	26%	10%	6%	5.50	38.2	3.5
17.92	16.1	1.7%	37%	21%	14%	31.10	76.3	5.5
13.77	22.9	3.0%	30%	10%	6%	2.44	213.0	2.0
2.41(1Q)	8.6	1.9%	46%	20%	10%	0.21	43.3	2.4
3.22(1Q)	8.3	3.3%	51%	19%	23%	0.92	78.1	1.7
	9MCY13 2.95 17.92 13.77 2.41(1Q)	9MCY13Exp PE*2.9526.717.9216.113.7722.92.41(1Q)8.6	9MCY13 Exp PE* Dividend Yield   2.95 26.7 3.0%   17.92 16.1 1.7%   13.77 22.9 3.0%   2.41(1Q) 8.6 1.9%	9MCY13Exp PE*Dividend YieldGP margin2.9526.73.0%26%17.9216.11.7%37%13.7722.93.0%30%2.41(1Q)8.61.9%46%	9MCY13 Exp PE* Dividend Yield GP margin EBIT margin   2.95 26.7 3.0% 26% 10%   17.92 16.1 1.7% 37% 21%   13.77 22.9 3.0% 30% 10%   2.41(1Q) 8.6 1.9% 46% 20%	9MCY13 Exp PE* Dividend Yield GP margin EBIT margin NPAT margin   2.95 26.7 3.0% 26% 10% 6%   17.92 16.1 1.7% 37% 21% 14%   13.77 22.9 3.0% 30% 10% 6%   2.41(1Q) 8.6 1.9% 46% 20% 10%	9MCY13 Exp PE* Dividend Yield GP margin EBIT margin NPAT margin Cash per share (Rs)   2.95 26.7 3.0% 26% 10% 6% 5.50   17.92 16.1 1.7% 37% 21% 14% 31.10   13.77 22.9 3.0% 30% 10% 6% 2.44   2.41(1Q) 8.6 1.9% 46% 20% 10% 0.21	9MCY13 Exp PE* Dividend Yield GP margin EBIT margin NPAT margin Cash per share (Rs) Book Value   2.95 26.7 3.0% 26% 10% 6% 5.50 38.2   17.92 16.1 1.7% 37% 21% 14% 31.10 76.3   13.77 22.9 3.0% 30% 10% 6% 2.44 213.0   2.41(1Q) 8.6 1.9% 46% 20% 10% 0.21 43.3

Source: www.scstrade.com

\*Our estimations

Disclaimer: This report has been prepared by Standard Capital Securities (Pvt) Ltd and is provided for information purposes only. The information and data on which this report is based are obtained from sources which we believe to be reliable but we do not guarantee that it is accurate or complete. Standard Capital Securities (Pvt) Ltd accepts no responsibility whatsoever for any direct or indirect consequential loss arising from any use of this report or its contents. Investors are advised to take professional advice before making investments and Standard Capital Securities (Pvt) Ltd does not take any responsibility and shall not be held liable for undue reliance on this report. This report may not be reproduced, distributed or published by any recipient for any purpose.